A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)

NCT07684612 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

690

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms

Interventions

DRUG: Mocertatug rezetecan (Mo-Rez)
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Gemcitabine
DRUG: Pegylated liposomal doxorubicin (PLD)
DRUG: Bevacizumab

Sponsor

GlaxoSmithKline

Collaborators

[object Object]